DOCSLIB.ORG

Fake COVID-19 Vaccination in India: an Emerging Dilemma?

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Fake COVID-19 Vaccination in India: an Emerging Dilemma? Postgrad Med J: first published as 10.1136/postgradmedj-2021-141003 on 26 August 2021. Downloaded from Letter Fake COVID-19 vaccination an antibiotic, amikacin, in place of the medications should be made available, vaccine.5 along with an ambulance on stand-by for in India: an When the CoWIN application (app) emergencies. emerging dilemma? was announced to be launched in India Vaccinator training programmes should as the application that handles registra- be run by the government and valid certif- tion and creates vaccine schedules, there icates should be verified with the state India, known to be the world’s largest were already fake CoWIN apps promising government department website before manufacturer and distributor of vaccines, people with vaccination. After the launch, enrolling individuals as vaccinators. Once started its free vaccine roll-outs against problems such as discrepancies in the vaccinated, patients should get a confir- COVID-19 on 16 January 2021.1 To information provided and slot allotments, mation message at once and should be administer vaccines to its 1380 million server issues with freezing and crashing advised not to leave the centre until the of the app revealed how unprepared the message is received. The CoWIN app at population, the National Expert Group system was to keep up with the increasing present does not account for comorbidi- on Vaccine Administration for COVID-19 user demand.6 The app also did not address ties and vaccine-associated adverse events. was formed to overlook collaborations at the estimated 18 million households in The app can be strengthened to incorpo- national, state and district levels for effec- India that have no working mobile phones rate data on demographics and adverse tive vaccine dissemination and roll- out.1 or access to the internet.7 These loopholes reactions. These data can be compiled Despite these efforts, as of 4 July 2021, provided an opportunity for fake vaccina- and shared with the public to make the 4.6% of the population are fully vacci- tors to target the vulnerable population. vaccination process more transparent and nated and 16.05% are partially vacci- Some fake apps also led to malicious links encourage more people to get vaccinated. nated.2 Among the eight vaccines that trying to hack people’s banking informa- In India the CBI coordinates with the are currently under various clinical trials, tion. A report from McAfee, a software INTERPOL and could implement strict initially only two were granted emergency security company, stated that out of the law enforcement for perpetrators leading use authorisation (EUA) by the Central 13 133 582 COVID-19- related malicious fake vaccination scams. A more structured Drugs Standard Control Organisation: files detected worldwide, 883 884 were and reliable system could streamline the (1) COVISHIELD by the Serum Institute detected in India alone.8 process and prevent vulnerable popula- of India and (2) COVAXIN by Bharat Although the government has halted tions from falling prey. Biotech.1 Sputnik V was later granted all other vaccination centres apart from Fake vaccines, apart from giving false EUA in April 2021.3 In the rising fear of government and private hospitals to sense of security with heightened risk the third wave, the country is acceler- tackle the situation, this slows down the of exposure to the disease, endanger a ating its vaccination efforts. Amidst these process and new strategies are needed to person’s health and may also erode trust efforts, there are surmounting allegations better deal with this unprecedented crisis. in legitimate vaccination programmes of people receiving fake vaccination in There should be well-organised system and lead to vaccine hesitancy, nullifying various parts of the country. and effective collaborations among efforts to reach mass immunisation. As When the COVID-19 vaccine drive various stakeholders to prevent these the world is racing to get vaccinated to initially started, the INTERPOL had mishaps. All vaccines must be delivered fight against the COVID-19 pandemic, issued warning across its 194 member from the Central Government vaccine fake vaccinations are slowing the pace countries that this arena could be a prime stores. There tends to be a high preva- and threatening the entire population. http://pmj.bmj.com/ target of criminal networks. Following lence of fake vaccines when the markets Organised planning, strong legislation this, in South Africa, 400 ampules, equiv- are unregulated and when private sectors and effective collaborations can help miti- alent to 2400 doses, of fake COVID-19 are involved.9 A minimum 70% efficacy gate this crisis. vaccines were dismantled from a ware- is needed for the vaccines, and respective house. A similar situation was seen in governments should conduct surveillance Dattatreya Mukherjee,1 Upasana Maskey ,2 China when police seized more than 3000 on the efficacy as well as the storage of Angela Ishak,2 Zouina Sarfraz ,3 4 fake vaccines. When reports of fake vacci- 10 Azza Sarfraz ,4 Vikash Jaiswal5 vaccines, so regulations need to be in on September 23, 2021 by guest. Protected copyright. nation surfaced in the Indian media, the place. Private vaccine centres could be 1Public Health, Jinan University, Guangzhou, country was shaken. Mumbai and Kolkata Guangdong, China allowed to purchase vaccines from the 2 saw the most harrowing situation associ- government but would still need to ask Clinical and Translational Research, Larkin Community ated with this racket, which culminated Hospital, South Miami, Florida, USA permission from the state health ministry 3Research and Publications, Fatima Jinnah Medical to be part of an organised syndicate. In and the local police so that proper records University, Lahore, Punjab, Pakistan Mumbai at least 2053 people were given can be maintained. The invoice and the 4Pediatrics and Child Health, The Aga Khan University, fake jabs of the vaccines at nine centres Karachi, Sindh, Pakistan permission letters should be made avail- 5 as part of vaccination drives/camps. An Medicine, AMA School of Medicine, Makati City, able on request. QR code scan-based Philippines entire housing committee was scammed batch number registration (identification) by fake vaccines and one hospital was in the government website should be Correspondence to Dr Azza Sarfraz, Department of even sealed for conducting a fake vacci- Pediatrics and Child Health, Faculty Office Building, Aga made mandatory before opening a vial. Khan University, P.O. Box: 3500, Stadium Road, Karachi nation drive. A special investigation team QR code scanning can be incorporated 74800, Pakistan; azza. sarfraz@ aku. edu was set up by the Mumbai Police which into the CoWIN app as well. The state Twitter Azza Sarfraz @Azzasarfraz arrested several people. A similar situa- ministry should create a zonal vaccination tion was witnessed in Kolkata, where 800 Acknowledgements We are thankful to Dr Giridara daily data collection office, and monthly Gopal for guiding us in this project and also to Tarun people were duped with fake jabs. In the checks should also be done by state repre- Kumar Suvvari for reviewing our paper. We are thankful fake vaccination drive, there are suspi- sentatives and police officials. These to our professors for guiding us. cions that people received either expired private centres should have one doctor Contributors All authors have contributed equally to vaccines, empty vials, saline water or as a central officer. Oxygen supplies and the drafting of this letter. Postgrad Med J Month 2021 Vol 0 No 0 1 Postgrad Med J: first published as 10.1136/postgradmedj-2021-141003 on 26 August 2021. Downloaded from Letter Funding The authors have not declared a specific Postgrad Med J 2021;0:1–2. 5 Sinha S. Kolkata fake Jab scam: Off- site vaccination grant for this research from any funding agency in the doi:10.1136/postgradmedj-2021-141003 camps halted, SOP to be issued. India today, 2021. public, commercial or not- for- profit sectors. Available: https://www. indiatoday. in/ cities/ kolkata/ ORCID iDs story/ vaccination- centres- cancelled- kolkata- fake- covid- Competing interests None declared. Upasana Maskey http:// orcid. org/ 0000- 0002- 3106- vaccine- 1820228- 2021- 06- 28 [Accessed 6 Jul 2021]. Patient consent for publication Not required. 4037 6 Desk T. CoWIN apps for download? health Ministry Provenance and peer review Not commissioned; Zouina Sarfraz http:// orcid. org/ 0000- 0002-5132- 7455 issues alert that these are fake. the Indian express, internally peer reviewed. Azza Sarfraz http:// orcid. org/ 0000- 0001- 8206- 5745 2021. Available: https:// indianexpress. com/ article/ technology/ tech- news- technology/ cowin- apps- for- This article is made freely available for use in download- health- ministry- issues- alert- that- these- are- accordance with BMJ’s website terms and conditions REFERENCES fake- 7136258/ [Accessed 13 Jul 2021]. for the duration of the covid-19 pandemic or until 1 Kumar VM, Pandi- Perumal SR, Trakht I, et al. Strategy 7 APCNews. The digital divide in India: How access to otherwise determined by BMJ. You may use, download for COVID-19 vaccination in India: the country with the technology and reliable information affects India’s and print the article for any lawful, non- commercial second highest population and number of cases. NPJ response to the pandemic | Association for Progressive purpose (including text and data mining) provided that Vaccines 2021;6:60. Communications. Apc. org, 2021. Available: https:// all copyright notices and trade marks are retained. 2 Mathieu E, Ritchie H, Ortiz- Ospina E. A global www. apc. org/ en/ node/ 37367 [Accessed 13 Jul 2021]. database of COVID-19 vaccinations. Nat Hum Behav © Author(s) (or their employer(s)) 2021. No commercial 8 et alMurti A, Kalia S, Kalia S. India among top targets re- use. See rights and permissions. Published by BMJ. 2021. for online fake vaccine Malware: report. The Swaddle, 3 Dong E, Du H, Gardner L.
Load more

Recommended publications
  • Determinants of Childhood Immunisation Coverage in Urban Poor Settlements of Delhi, India: a Cross-Sectional Study
    Open Access Research BMJ Open: first published as 10.1136/bmjopen-2016-013015 on 26 August 2016. Downloaded from Determinants of childhood immunisation coverage in urban poor settlements of Delhi, India: a cross-sectional study Niveditha Devasenapathy,1 Suparna Ghosh Jerath,1 Saket Sharma,1 Elizabeth Allen,2 Anuraj H Shankar,3 Sanjay Zodpey1 To cite: Devasenapathy N, ABSTRACT Strengths and limitations of this study Ghosh Jerath S, Sharma S, Objectives: Aggregate data on childhood et al. Determinants of immunisation from urban settings may not reflect the ▪ childhood immunisation We report current estimates of childhood com- coverage among the urban poor. This study provides coverage in urban plete immunisation including hepatitis B vaccine poor settlements of Delhi, information on complete childhood immunisation coverage from representative urban poor com- India: a cross-sectional study. coverage among the urban poor, and explores its munities in the Southeast of Delhi. BMJ Open 2016;6:e013015. household and neighbourhood-level determinants. ▪ The sample size was large and therefore our doi:10.1136/bmjopen-2016- Setting: Urban poor community in the Southeast effect estimates for coverage and determinants 013015 district of Delhi, India. were precise. Participants: We randomly sampled 1849 children ▪ We quantify unknown neighbourhood effects on ▸ Prepublication history and aged 1–3.5 years from 13 451 households in 39 this outcome using median ORs which are more additional material is clusters (cluster defined as area covered by a intuitively understood. available. To view please visit community health worker) in 2 large urban poor ▪ Based on the data, representative of only one the journal (http://dx.doi.org/ settlements.
    [Show full text]
  • Analysis of the Universal Immunization Programme and Introduction
    Vaccine 32S (2014) A151–A161 Contents lists available at ScienceDirect Vaccine j ournal homepage: www.elsevier.com/locate/vaccine Analysis of the Universal Immunization Programme and introduction of a rotavirus vaccine in India with IndiaSim a a,b a c Itamar Megiddo , Abigail R. Colson , Arindam Nandi , Susmita Chatterjee , d e a,b,c,∗ Shankar Prinja , Ajay Khera , Ramanan Laxminarayan a Center for Disease Dynamics, Economics & Policy, Washington, DC, USA b Princeton Environmental Institute, Princeton University, Princeton, NJ, USA c Public Health Foundation of India, New Delhi, India d School of Public Health, Postgraduate Institute of Medical Education and Research, Chandigarh, India e Ministry of Health and Family Welfare, Government of India, New Delhi, India a b s t r a c t Background and objectives: India has the highest under-five death toll globally, approximately 20% of which is attributed to vaccine-preventable diseases. India’s Universal Immunization Programme (UIP) is working both to increase immunization coverage and to introduce new vaccines. Here, we analyze the disease and financial burden alleviated across India’s population (by wealth quintile, rural or urban area, and state) through increasing vaccination rates and introducing a rotavirus vaccine. Methods: We use IndiaSim, a simulated agent-based model (ABM) of the Indian population (including socio-economic characteristics and immunization status) and the health system to model three interventions. In the first intervention, a rotavirus vaccine is introduced at the current DPT3 immunization coverage level in India. In the second intervention, coverage of three doses of rotavirus and DPT and one dose of the measles vaccine are increased to 90% randomly across the population.
    [Show full text]
  • Why Is the Vaccination Rate Low in India?
    medRxiv preprint doi: https://doi.org/10.1101/2021.01.21.21250216; this version posted February 18, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Why is the Vaccination Rate Low in India? First Version: 21st January 2021 This Version: 15th February 2021 Pramod Kumar Sur Asian Growth Research Institute (AGI) and Osaka University [email protected] Abstract India has had an established universal immunization program since 1985 and immunization services are available for free in healthcare facilities. Despite this, India has one of the lowest vaccination rates globally and contributes to the largest pool of under-vaccinated children in the world. Why is the vaccination rate low in India? This paper explores the importance of historical events in shaping India’s current vaccination practices. We examine India’s aggressive family planning program implemented during the period of emergency rule in the 1970s, under which millions of individuals were forcibly sterilized. We find that greater exposure to the forced sterilization policy has had negative effects on the current vaccination rate. We also find that institutional delivery and antenatal care are currently low in states where policy exposure is high. Together, the evidence suggests that the forced sterilization policy has had a persistent effect on current health-seeking behavior in India. Keywords: Vaccination, family planning, sterilization, institutional delivery, antenatal care, persistence JEL Classification: N35, I15, I18, O53, Z1 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
    [Show full text]
  • A Brief History of Vaccines & Vaccination in India
    [Downloaded free from http://www.ijmr.org.in on Wednesday, August 26, 2020, IP: 14.139.60.52] Review Article Indian J Med Res 139, April 2014, pp 491-511 A brief history of vaccines & vaccination in India Chandrakant Lahariya Formerly Department of Community Medicine, G.R. Medical College, Gwalior, India Received December 31, 2012 The challenges faced in delivering lifesaving vaccines to the targeted beneficiaries need to be addressed from the existing knowledge and learning from the past. This review documents the history of vaccines and vaccination in India with an objective to derive lessons for policy direction to expand the benefits of vaccination in the country. A brief historical perspective on smallpox disease and preventive efforts since antiquity is followed by an overview of 19th century efforts to replace variolation by vaccination, setting up of a few vaccine institutes, cholera vaccine trial and the discovery of plague vaccine. The early twentieth century witnessed the challenges in expansion of smallpox vaccination, typhoid vaccine trial in Indian army personnel, and setting up of vaccine institutes in almost each of the then Indian States. In the post-independence period, the BCG vaccine laboratory and other national institutes were established; a number of private vaccine manufacturers came up, besides the continuation of smallpox eradication effort till the country became smallpox free in 1977. The Expanded Programme of Immunization (EPI) (1978) and then Universal Immunization Programme (UIP) (1985) were launched in India. The intervening events since UIP till India being declared non-endemic for poliomyelitis in 2012 have been described. Though the preventive efforts from diseases were practiced in India, the reluctance, opposition and a slow acceptance of vaccination have been the characteristic of vaccination history in the country.
    [Show full text]
  • IJPP Hemotology 9-2-08
    2009; 11(1) : 1 INDIAN JOURNAL OF IJPP PRACTICAL PEDIATRICS • • IJPP is a quarterly subscription journal of the Indian Academy of Pediatrics committed to presenting practical pediatric issues and management updates in a simple and clear manner • • Indexed in Excerpta Medica, CABI Publishing. Vol.11 No.1 JAN.-MAR.2009 Dr. K.Nedunchelian Dr. S. Thangavelu Editor-in-Chief Executive Editor CONTENTS FROM THE EDITOR'S DESK 3 TOPIC OF INTEREST - TOXICOLOGY Organophosphate, carbamate and rodenticide poisoning 6 - Rajendiran C, Ravi G, Thirumalaikolundu Subramanian P Hydrocarbon and related compounds poisoning 15 - Utpal Kant Singh, Prasad R, Gaurav A Common drug poisoning 22 - Suresh Gupta Corrosive poisoning 37 - Jayanthi Ramesh House hold material poisoning 41 - Shuba S, Betty Chacko Cardiotoxins 53 - Rashmi Kapoor Narcotic poisoning 64 - Kala Ebinazer Journal Office and address for communications: Dr. K.Nedunchelian, Editor-in-Chief, Indian Journal of Practical Pediatrics, 1A, Block II, Krsna Apartments, 50, Halls Road, Egmore, Chennai - 600 008. Tamil Nadu, India. Tel.No. : 044-28190032 E.mail : [email protected] 1 Indian Journal of Practical Pediatrics 2009; 11(1) : 2 GENERAL ARTICLES Intrauterine growth retardation : Journey from conception to late adulthood 68 - Neelam Kler, Naveen Gupta Child adoption 82 - Ganesh R, Suresh N, Eswara Raja T, Lalitha Janakiraman, Vasanthi T DERMATOLOGY Ichthyosis - An approach 86 - Anandan V PICTURE QUIZ 91 RADIOLOGIST TALKS TO YOU Disorders of ventral induction and similar conditions - I 92 - Vijayalakshmi G, Elavarasu E, Vijayalakshmi M, Venkatesan MD CASE STUDY Unusual complication of nasogastric tube insertion in a child 95 - Poovazhagi V, Shanthi S, Vijayaraghavan A, Kulandai Kasturi R Congenital miliary tuberculosis 97 - Vijayakumari, Suresh DV CLIPPINGS 14,21,52,63,81,94 NEWS AND NOTES 85,90 FOR YOUR KIND ATTENTION * The views expressed by the authors do not necessarily reflect those of the sponsor or publisher.
    [Show full text]
  • Strategy for COVID-19 Vaccination in India: the Country with the Second Highest Population and Number of Cases ✉ Velayudhan Mohan Kumar 1, Seithikurippu R
    www.nature.com/npjvaccines PERSPECTIVE OPEN Strategy for COVID-19 vaccination in India: the country with the second highest population and number of cases ✉ Velayudhan Mohan Kumar 1, Seithikurippu R. Pandi-Perumal 2 , Ilya Trakht3 and Sadras Panchatcharam Thyagarajan 4 Free vaccination against COVID-19 commenced in India on January 16, 2021, and the government is urging all of its citizens to be immunized, in what is expected to be the largest vaccination program in the world. Out of the eight COVID-19 vaccines that are currently under various stages of clinical trials in India, four were developed in the country. India’s drug regulator has approved restricted emergency use of Covishield (the name employed in India for the Oxford-AstraZeneca vaccine) and Covaxin, the home- grown vaccine produced by Bharat Biotech. Indian manufacturers have stated that they have the capacity to meet the country’s future needs for COVID-19 vaccines. The manpower and cold-chain infrastructure established before the pandemic are sufficient for the initial vaccination of 30 million healthcare workers. The Indian government has taken urgent measures to expand the country’s vaccine manufacturing capacity and has also developed an efficient digital system to address and monitor all the aspects of vaccine administration. npj Vaccines (2021) 6:60 ; https://doi.org/10.1038/s41541-021-00327-2 1234567890():,; INTRODUCTION eight vaccine candidates, currently undergoing clinical trials in A year has passed since the first case of novel coronavirus India, is shown in Table 1 and their technical details are given in 13 infections was detected in China’s Wuhan province.
    [Show full text]
  • JANUARY 2014 S. No Principal Investigator Department Title Fund
    LIST OF STUDIES WITH RESPECTIVE FUNDING AGENCY JANUARY 2006 – JANUARY 2014 Principal S. No Department Title Funding Agency Investigator A randomized, double-blind, placebo-controlled, parallel group study to determine whether, in patients with type 2 diabetes at AACT – Academic 1 Dr. Nihal Thomas Endocrinology high risk for cardiovascular and renal events, aliskiren, on top of Alliance for Clinical conventional treatment, reduces cardiovascular and renal Trials morbidity and mortality. This prospective, open label, multi –center, observational, single- 2 Dr. Sunil Chandy Cardiology arm registry is designed to XIENCE VEECSS continued safety and Abbott Vascular effectiveness during commercial use in real world settings. Prospective, randomized, placebo-controlled, double-blind, Dr. Debashish Clinical Immunology multicenter, parallel group study to assess the efficacy, safety and 3 Actelion Danda & Rheumatology tolerability of macitentan in patients with ischemic digital ulcers associated with systemic sclerosis. Targeted Second- Generation Resequencing for the Molecular 4 Dr. Nihal Thomas Endocrinology Genetic Diagnosis of Maturity Onset Diabetes of the Young Actelion (MODY). A randomized, active therapy controlled phase 2 study to assess Advaxis Inc, North 5 Dr. Subhashini John Radiation Therapy the safety and efficacy of ADXS11-001 with or without Cisplatin Brunswick as 2nd line therapy for the treatment of recurrent cervix cancer. A multicentre, open label, parallel group, randomized, phase IIB Adventrux Dr. Raju Titus clinical trial to evaluate the safety and efficacy of CofactorTM and 6 Medical Oncology Pharmaceuticals, Chacko 5-FU versus Leucovorin and 5-FU in subjects with Metastatic USA colorectal carcinoma. FORTIS-M: A phase 3, randomized, double-blind, placebo- controlled study of oral talactoferrin in addition to best 7 Dr.
    [Show full text]
  • Modelling the Impact of a Smallpox Attack in India and Influence of Disease Control Measures
    Open access Original research BMJ Open: first published as 10.1136/bmjopen-2020-038480 on 13 December 2020. Downloaded from Modelling the impact of a smallpox attack in India and influence of disease control measures Biswajit Mohanty,1 Valentina Costantino ,2 Jai Narain,1 Abrar Ahmad Chughtai,1 Arpita Das,2 C Raina MacIntyre 2 To cite: Mohanty B, ABSTRACT Strengths and limitations of this study Costantino V, Narain J, et al. Objectives To estimate the impact of a smallpox attack Modelling the impact of a in Mumbai, India, examine the impact of case isolation ► The model takes into account heterogeneity of age, smallpox attack in India and ring vaccination for epidemic containment and test and influence of disease disease transmission and immunological levels. the health system capacity under different scenarios with control measures. BMJ Open ► Age- specific rates of immunosuppressive condi- available interventions. 2020;10:e038480. doi:10.1136/ tions were estimated for Mumbai and included in Setting The research is based on Mumbai, India bmjopen-2020-038480 the model. population. ► This study does not include different route of trans- ► Prepublication history and Interventions We tested 50%, 70%, 90% of case mission than airborne. additional material for this paper isolation and contacts traced and vaccinated (ring is available online. To view these ► Other aspects that could influence transmission in- vaccination) in the susceptible, exposed, infected, files, please visit the journal clude seasonality, or vaccination effectiveness such recovered model and varied the start of intervention online (http:// dx. doi. org/ 10. as vaccine refusal were not included in the model.
    [Show full text]
  • March 2021 Issue
    E-copy VOLUME 58 NUMBER 03 MARCH 2021 Copyright of Indian Pediatrics. It is meant for personal use only, and not to be shared widely over social media platforms, blogs and mass e-mails. ADVERTISEMENT INDIAN PEDIATRICS 209 VOLUME 58__MARCH 15, 2021 ADVERTISEMENT INDIAN PEDIATRICS 210 VOLUME 58__MARCH 15, 2021 Indian Pediatrics March 2021 Volume 58 Number 3 Editor-in-Chief Devendra Mishra CONTENTS Executive Editor Siddarth Ramji Managing Editor Rakesh Lodha PRESIDENT’S PAGE Associate Editors Anup Mohta Mumbai 2021 Call for Action: Addressing the Need to Incorporate Pooja Dewan Joseph L Mathew ‘Nurturing Care for Early Childhood Development’ in Pediatric Office Aashima Dabas Practice–PIYUSH GUPTA, GV BASAVARAJA, RANJAN PEJAVER, DINESH T OMAR, Executive Members Abhijit Saha ALPESH GANDHI AND JAYDEEP TANK 215 JS Kaushik Sunita Bijarnia EDITORIAL COMMENTARY Rachna Seth Somshekhar Nimbalkar Immunization in Special Situations–SANJIB MONDAL AND SURJIT SINGH 217 Ujjal Poddar PERSPECTIVE Sanjay Verma Kirtisudha Mishra Evolution Bites - Timeworn Inefficacious Snakebite Therapy in the Ashish Jain Era of Recombinant Vaccines–NAVNEET KAUR, ASHWIN I YER AND Kana Ram Jat Sumaira Khalil KARTIK SUNAGAR 219 Romit Saxena RESEARCH PAPERS International Advisory Board Prashant Mahajan (USA) Three vs Four Dose Schedule of Double Strength Recombinant Sanjay Mahant (Canada) Hepatitis-B Vaccine in HIV-infected Children: A Randomized Controlled PSN Menon (Kuwait) John M Pettifor (South Africa) Trial–PRACHI JAIN, POOJA DEWAN, SUNIL GOMBER, BINEETA KASHYAP AND SudhinThayyil
    [Show full text]
  • Effective Supportive Supervision in Immunization Health Systems
    Effective Supportive Supervision in Immunization Health Systems Strengthening Case Study Madhya Pradesh, India April 2020 i) Acknowledgements This case study is an outcome of a consultative engagement involving a range of stakeholders in Madhya Pradesh and beyond working in health systems and particularly immunization. Everyone who has been interviewed during the process showed tremendous enthusiasm and passion for the system and were supportive of the documentation exercise. We are thankful to the senior officials of Madhya Pradesh Directorate of Health Services and National Health Mission, Dr. Santosh Shukla, Mr. Vipin Srivastava and Dr. Ashwin Bhagwat for their critical inputs to this process and facilitating the entire data collection endeavor. The colleagues at Gandhi Medical College, led by Dr. D.K. Pal were gracious to explain the entire supportive supervision initiative and making available the relevant datasets. We also extend our gratitude to the district and block level officials and frontline health workers, who spared their time and ensured that the schedule of data collection is followed as per the plan. Finally, this work could not have been done without the supervision of Dr. Claudia Vivas and her team in New York, Dr. Rija Andriamihantanirina and his team in New Delhi and Dr. Vandana Bhatia and her team in Bhopal. ii) Acronyms AEFI Adverse Events Following Immunization ANM Auxiliary Nurse Midwife ASHA Accredited Social Health Activist AVDS Alternate Vaccine Delivery System AWW AnganWadi Worker AYUSH Ayurveda, Yoga & Naturopathy,
    [Show full text]
  • Heterologous Protection to COVID-19 with BCG Vaccine: Deciphering the Reality Using Meta-Analysis Approach
    Singh A, Gupta L, Gupta V. Heterologous Protection to COVID-19 with BCG Vaccine: Deciphering the Reality Using Meta-Analysis Approach. J Immunological Sci. (2020); 4(4): 34-40 Journal of Immunological Sciences Original Research Article Open Access Heterologous Protection to COVID-19 with BCG Vaccine: Deciphering the Reality Using Meta-Analysis Approach Anurag Singh1, Lakshya Gupta2, Vandana Gupta1* 1Department of Microbiology, Ram Lal Anand College, University of Delhi, Benito Juarez Road, New Delhi 110021, India 2Department of Computer Science and Engineering, Indian Institute of Technology, Varanasi, Uttar Pradesh 221005, India. Article Info ABSTRACT Article Notes The coronavirus disease (COVID-19) emerged in China in December 2019 Received: October 07, 2020 and has since spread to over 188 countries affecting millions of individuals. Accepted: December 11, 2020 Several reports in favour or against the heterologous protection conferred by the *Correspondence: BCG vaccine against COVID-19 came up in the initial days of the pandemic and *Dr. Vandana Gupta, Department of Microbiology, Ram Lal continue to do so. In this study, we compared the three worst-affected nations: Anand College, University of Delhi, Benito Juarez Road, New The USA, India, and Brazil, their current pandemic scenario, and their respective Delhi 110021, India; Email: [email protected]. national BCG immunization policies. USA recommends BCG vaccine only to a specific group of people and never had a national immunization scheme in © 2020 Gupta V. This article is distributed under the terms of place. Meanwhile, India introduced a nationwide scheme as early as 1948 and the Creative Commons Attribution 4.0 International License. continues to endorse BCG immunization at birth.
    [Show full text]
  • Impacts of Community-Led Video Education to Increase Vaccination Coverage in Uttar Pradesh, India: a Mixed Methods Randomised Controlled Trial
    Impacts of community-led video education to increase vaccination coverage in Uttar Pradesh, India: A mixed methods randomised controlled trial Nikki Gurley PATH Jessica Shearer PATH Yachna Srivastava PATH Sudip Mahapatra PATH Michelle Desmond PATH Grantee Final Report Accepted by 3ie: June 2020 Note to readers This impact evaluation has been submitted in fulfilment of requirements under grant TW10.1039 issued under Innovations in Increasing Immunisation Evidence Programme. This version is being published online as it was received. A copy-edited and formatted version will be available in the 3ie Impact Evaluation Report Series in the near future. All content is the sole responsibility of the authors and does not represent the opinions of 3ie, its donors or its board of commissioners. Any errors and omissions are the sole responsibility of the authors. All affiliations of the authors listed in the title page are those that were in effect at the time the report was accepted. Any comments or queries should be directed to the corresponding author, Nikki Gurley at: [email protected]. The 3ie technical quality assurance team comprises Monica Jain, Avantika Bagai, Ananta Seth, Kirthi Rao, Sayak Khatua, an anonymous external impact evaluation design expert reviewer and an anonymous external sector expert reviewer, with overall technical supervision by Marie Gaarder. Funding for this impact evaluation was provided by Bill & Melinda Gates Foundation. A complete listing of all of 3ie’s donors is available on the 3ie website. Suggested citation: Gurley, N, Shearer, J, Srivastava, Y, Mahapatra, S and Desmond, M, 2020. Impacts of community-led video education to increase vaccination coverage in Uttar Pradesh, India: A mixed methods randomised controlled trial, 3ie Grantee Final Report.
    [Show full text]